NEW YORK, May 24 - Oxford GlycoSciences today said it has hired David Ebsworth to take over the CEO post after Michael Kranda leaves on July 11.
Ebsworth, 47, will be "CEO Designate" and formally begin on July 1, according to OGS. He will work alongside Kranda, who cited family reasons for his departure.
The new CEO comes to OGS from Bayer, where he ran its worldwide pharmaceutical business. Before that he was president of the German giant's North American pharmaceutical division.
Click here for more information.